SCHEMBL3570210

SCHEMBL3570210

CNc1ccc(Cl)cc1C(=O)N(CCc1cccc(C(F)(F)F)c1)Cc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
NR4A2 P43354 1/20 0.44
PDGFRA P16234 1/20 0.44
S1PR1 P21453 1/20 0.44
S1PR5 Q9H228 1/20 0.44
SLC2A1 P11166 2/20 0.44
MAOB P27338 2/20 0.43
LPAR1 Q92633 1/20 0.43
LPAR5 Q9H1C0 1/20 0.43
MBTPS1 Q14703 1/20 0.43
KLK1 P06870 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LRRK2 Q5S007 1/20 0.41
GPR34 Q9UPC5 1/20 0.41
ADAMTS4 O75173 1/20 0.40
MMP13 P45452 1/20 0.40
ADAMTS5 Q9UNA0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3577779 0.95 FFAR1 (0.43) FFAR1FFAR4NR4A2PDGFRAS1PR1
SCHEMBL3574032 0.93 FFAR1 (0.41) FFAR1FFAR4NR4A2PDGFRAS1PR1
SCHEMBL3581565 0.90 SLC2A1 (0.43) FFAR1FFAR4PDGFRAS1PR1S1PR5
SCHEMBL3575570 0.89 TRPV1 (0.42) SLC2A1LPAR1LPAR5
SCHEMBL3585679 0.89 LMNA (0.44) S1PR1S1PR5SLC2A1LPAR1LPAR5
SCHEMBL3576064 0.89 LMNA (0.46) FFAR1FFAR4PDGFRAS1PR1S1PR5
SCHEMBL3579168 0.89 SLC2A1 (0.41) SLC2A1LPAR1LPAR5
SCHEMBL3576819 0.88 SLC2A1 (0.41) FFAR1FFAR4PDGFRAS1PR1S1PR5
SCHEMBL3584461 0.87 LMNA (0.44) S1PR1S1PR5SLC2A1LPAR1LPAR5
SCHEMBL3573413 0.87 LMNA (0.44) SLC2A1LPAR1LPAR5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC FFAR1 1955/4885FFAR4 2522/4885NR4A2 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.